Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Julphar
Citi
Cipla
Baxter
Boehringer Ingelheim
Cantor Fitzgerald
Teva
Colorcon

Generated: July 21, 2018

DrugPatentWatch Database Preview

VIBATIV Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for VIBATIV
Generic Entry Opportunity Date for VIBATIV
Generic Entry Date for VIBATIV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VIBATIV
Synonyms for VIBATIV
0701472ZG0
372151-71-8
560130-42-9
AC1MIWRX
AM006875
Arbelic
CHEBI:71226
CHEBI:71229
CHEMBL3301680
CHEMBL507870
D02IJB
D06057
D0B9JO
DB06402
HSDB 8194
LS-192933
N(3'')-[2-(decylamino)ethyl]-29-{[(phosphonomethyl)amino]methyl}vancomycin
SCHEMBL8287015
SIB-1533A
T-1455
Td 6424
TD-6424
Telavancin
Telavancin [INN]
Telavancin HCl
Telavancin Hydrochloride
Telavancin hydrochloride (USAN)
Telavancin hydrochloride [USAN]
Telavancin, Antibiotic for Culture Media Use Only
telavancina
telavancine
telavancinum
UNII-0701472ZG0
UNII-XK134822Z0
Vancomycin, N3'-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-, monohydrochloride
Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-
Vibativ (TN)
XK134822Z0

US Patents and Regulatory Information for VIBATIV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-002 Sep 11, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for VIBATIV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,157,554 Glycopeptide carboxy-saccharide derivatives ➤ Sign Up
6,872,804 Glycopeptide disulfide and thioester derivatives ➤ Sign Up
6,887,976 Glycopeptide phosphonate derivatives ➤ Sign Up
6,620,781 Glycopeptide carboxy-saccharide derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for VIBATIV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00033 Denmark ➤ Sign Up PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID
2011100062 Germany ➤ Sign Up PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
C/GB11/056 United Kingdom ➤ Sign Up PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
C0051 France ➤ Sign Up PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Army
Argus Health
QuintilesIMS
Chinese Patent Office
McKinsey
Harvard Business School
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.